Literature DB >> 15857940

Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP.

Rosa P Gomariz1, Alicia Arranz, Catalina Abad, Marta Torroba, Carmen Martinez, Florencia Rosignoli, Maria Garcia-Gómez, Javier Leceta, Yasmina Juarranz.   

Abstract

Toll-like receptor 2 (TLR2) and -4 mediate signals from a great variety of bacterial gut products, giving the host a panel of microbe-recognizing receptors. Under homeostatic conditions, TLRs act as protective receptors of the intestinal epithelium. When homeostasis is disrupted in diseases such as inflammatory bowel disease, TLR2 and -4 are deregulated. Our study demonstrates, by using a trinitrobenzene sulfonic acid-induced colitis model of Crohn's disease, the constitutive expression and the up-regulation of TLR2 and -4 at messenger and protein levels in colon extracts, as well as in macrophages, dendritic cells, and lymphocytes from mesenteric lymphoid nodes. Vasoactive intestinal peptide (VIP) treatment induced a decrease of TLR2 and -4 expressions approaching ethanol control levels. Our results suggest that VIP modulation of TLR2 and -4 could be explained by two possible mechanisms. The first one would be the secondary reduction of TLR2 and -4 caused by the VIP-mediated decrease of inflammatory mediators such as interleukin-1beta and interferon-gamma, which synergize with bacterial products, contributing to the amplification of TLR presence in the intestine. The other possible mechanism would involve a VIP-mediated decrease of nuclear factor-kappaB, which would cause a direct down-regulation of TLR expression. In summary, the resultant physiological effect is the decrease of TLR2 and -4 expressions to homeostatic levels. Our study describes for the first time the role of a peptide present in the gut microenvironment as an effective modulator of the initial steps of acute inflammation, acting at local and systemic levels and leading to the restoration of the homeostasis lost after an established inflammatory/autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857940     DOI: 10.1189/jlb.1004564

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  30 in total

Review 1.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

2.  Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders.

Authors:  Alejo Chorny; Elena Gonzalez-Rey; Amelia Fernandez-Martin; David Pozo; Doina Ganea; Mario Delgado
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

Review 3.  The Enteric Network: Interactions between the Immune and Nervous Systems of the Gut.

Authors:  Bryan B Yoo; Sarkis K Mazmanian
Journal:  Immunity       Date:  2017-06-20       Impact factor: 31.745

Review 4.  Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens.

Authors:  Esther M Sternberg
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

5.  Focal, but not global, cerebral ischaemia causes loss of myenteric neurons and upregulation of vasoactive intestinal peptide in mouse ileum.

Authors:  Xiaowen Cheng; Martina Svensson; Yiyi Yang; Tomas Deierborg; Eva Ekblad; Ulrikke Voss
Journal:  Int J Exp Pathol       Date:  2018-03-25       Impact factor: 1.925

6.  Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties.

Authors:  Qiaoli Liang; Qinan Wu; Jihong Jiang; Jin'ao Duan; Chao Wang; Mark D Smith; Hong Lu; Qian Wang; Prakash Nagarkatti; Daping Fan
Journal:  J Biol Chem       Date:  2011-06-10       Impact factor: 5.157

Review 7.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

8.  Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis.

Authors:  Brad A Pasternak; Sharon D'Mello; Ingrid I Jurickova; Xiaonan Han; Tara Willson; Leah Flick; Lisa Petiniot; Naonori Uozumi; Senad Divanovic; Anna Traurnicht; Erin Bonkowski; Subra Kugathasan; Christopher L Karp; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

Review 9.  Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function.

Authors:  Maria T Abreu
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

10.  IL-10-dependent partial refractoriness to Toll-like receptor stimulation modulates gut mucosal dendritic cell function.

Authors:  Ivan Monteleone; Andrew M Platt; Elin Jaensson; William W Agace; Allan McI Mowat
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.